Prot #R2810-ONC-1620: A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of

Project: Research project

StatusActive
Effective start/end date12/1/1712/1/20

Funding

  • ICON Clinical Research Limited (Prot #R2810-ONC-1620)
  • Regeneron Pharmaceuticals, Inc. (Prot #R2810-ONC-1620)